Viewing StudyNCT01253096

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-05 @ 11:05 PM
Last Modification Date: 2024-10-26 @ 10:28 AM
Study NCT ID: NCT01253096
Status: COMPLETED
Last Update Posted: 2014-11-20
First Post: 2010-12-02
Brief Title: Intratumoral Application of L19IL2 in Patients With Malignant Melanoma
Sponsor: Philogen SpA
Organization: Philogen SpA
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Malignant Melanoma
Keywords:
Name View
Interleukin View
IL2 View
monoclonal View
antibody View
cytokine View
metastatic View
melanoma View
tumor targeting View
intratumoral View
Malignant melanoma with presence of injectable soft-tissue metastases either in clinical stage III or stage IV without visceral metastases View